ASB2 Is an Elongin BC-interacting Protein That Can Assemble with Cullin 5 and Rbx1 to Reconstitute an E3 Ubiquitin Ligase Complex*

Received for publication, November 18, 2004

Méлина L. Heuze‡§, Florence C. Guibal¶¶, Charles A. Banks‡, Joan W. Conaway¶, Ronald C. Conaway¶, Yvon E. Cayré***, Arndt Benecke‡‡, and Pierre G. Lutz‡§

From the §INSERM, U417, Hôpital Robert Debré, 48 Boulevard Serurier, F-75895 Paris Cedex 19, France, ¶Stowers Institute for Medical Research, Kansas City, Missouri 64110, ¶¶Department of Microbiology/Immunology, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-5541, §§University La Sapienza II, Roma 00161, Italy, and ¶¶¶Institut des Hautes Études Scientifiques, 35 route de Chartres, F-91440 Bures-sur-Yvette, France

The ankyrin repeat-containing protein with a suppressor of cytokine signaling box-2 (ASB2) gene was identified as a retinoic acid-response gene and a target of the promyelocytic leukemia-retinoic acid receptor-α oncogenic protein characteristic of acute promyelocytic leukemia. Expression of ASB2 in myeloid leukemia cells inhibits growth and promotes commitment, recapitulating an early step known to be critical for differentiation. Here we show that ASB2, by interacting with the Elongin BC complex, can assemble with Cullin5-Rbx1 to form an E3 ubiquitin ligase complex that stimulates polyubiquitination by the E2 ubiquitin-conjugating enzyme Ubc5. This is a first indication that a member of the ASB protein family, ASB2, is a subunit of an ECS (Elongin C-Cullin-SOCS box)-type E3 ubiquitin ligase complex. Altogether, our results strongly suggest that ASB2 targets specific proteins to destruction by the proteasome in leukemia cells that have been induced to differentiate.

Identification of genes controlling proliferation and differentiation of myeloid cells is critical for understanding how myelopoiesis is dysregulated by chromosomal abnormalities in leukemia cells. Because committed hematopoietic progenitors are likely targets for leukemic transformation, genes involved in myeloid differentiation might be repressed in leukemia cells and activated when these cells are exposed to agents that induce differentiation. Acute promyelocytic leukemia (APL)1 is associated with five reciprocal translocations always involving the retinoic acid receptor α (RARα) (1, 2).

RARα is a retinoic acid (RA)-dependent transcription factor (3) involved in hematopoietic differentiation (4). Although RARs are dispensable for granulopoiesis (5), a role for RA in the commitment of hematopoietic progenitors into the granulocytic lineage has been proposed (6–8). Furthermore, overexpression of wild-type RARs or dominant-negative forms of RARα indicating PML-RARα blocks granulocytic differentiation at the promyelocytic stage (9, 10). These findings suggest that RARα may inhibit neutrophil differentiation when unbound and promote differentiation when bound to its specific ligand. In more than 95% of APL, the specific translocation t(15;17) produces the PML-RARα fusion proteins. Although most patients express the reciprocal RARα-PML protein, some do not, suggesting that RARα-PML may be dispensable for leukemogenesis. The association of histone deacetylases with PML-RARα has been described in APL cells (11–13), suggesting that PML-RARα may recruit a histone deacetylase complex leading to the repression of RA target genes critical to myeloid differentiation. It has been shown that the histone deacetylase complex dissociates from the PML-RARα fusion protein in the presence of pharmacological concentrations of RA, suggesting a mechanism by which APL cells are sensitive to RA treatment (11–13). Indeed, when treated with RA, these cells withdraw from the cell cycle and undergo terminal maturation both in vitro (14) and in vivo (15–17). This suggests a molecular mechanism by which RA-responsive genes critical to myeloid differentiation are repressed in leukemia cells and derepressed when these cells are treated with RA. A few PML-RARα target genes have been identified including (i) PRAM-1, a novel molecular adapter of myeloid cells (18), (ii) ASB2, a member of the suppressors of cytokine signaling (SOCS) protein family (19), (iii) p21WAF1/CIP1, a mediator of growth inhibition that plays a role during commitment to differentiation of RA-treated APL cell (20), (iv) ubiquitin-activating enzyme E1-like (UBE1L), which mediates PML-RARα ubiquitination and subsequent degradation (21), and (v) the CCAAT/enhancer binding proteins (C/EBPs) β and ε, which are myeloid transcription factors (22, 23). C/EBPε is the only example of a gene that is up-regulated by RA in APL cells and dominantly repressed by PML-RARα and whose expression is required for the reactivation of the differentiation program.

The ASB2 gene was isolated by applying a subtractive hybridization strategy to identify novel genes activated during RA-induced maturation of APL cells (24). ASB2 is both a PML-RARα target and a RA-response gene (19). Expression of the ASB2 protein in myeloid leukemia cells inhibits growth and promotes chromatin condensation, which are characteristics of commitment known as critical to differentiation of myeloid
leukemia cells (19). The ASB2 gene encodes a protein harboring ankyrin repeats, a protein-protein interaction domain, and a BC motif located within a SOCS box. By interacting with the Elongin BC complex through the BC motif, several proteins containing a BC motif are able to assemble into an ECS (Elongin C-Cullin-SOCS box)-type E3 ubiquitin ligase complex that functions with the E1 ubiquitin-activating enzyme and an E2 ubiquitin-conjugating enzyme to ubiquitinate its specific partners (25). These targets are then degraded by the proteasome machinery. The mammalian Elongin BC complex, which is a heterodimer composed of the Elongin B and Elongin C proteins, was initially identified as a positive regulator of RNA polymerase II elongation factor Elongin A (26, 27) and subsequently as a component of the von Hippel Lindau (VHL) tumor suppressor complex (28, 29). Both Elongin A and VHL protein have been shown to bind to Elongin C via interaction with the highly conserved leucine residue at position 2 of the BC box (30, 31). Elongin B binds to Elongin C and does not interact directly with the BC box. The Elongin BC complex functions as an adaptor that links the BC box-containing protein to cullin (Cul) 2 or 5, which in turn binds to the ring finger protein Rbx1 to reconstitute a multisubunit complex with ubiquitin ligase activity (32–35). Within this complex, the BC-box protein is also involved in the recruitment of specific targets, suggesting that BC-box proteins regulate turnover of proteins by targeting them for proteasomal degradation. Indeed, the VHL protein can be considered as the receptor subunit of an E3 ubiquitin ligase complex. Consequently, the VHL-ubiquitination machinery controls the stability of hypoxia-inducible transcription factor HIF1α by promoting its ubiquitination and proteasome-dependent degradation (36–38).

In an attempt to decipher the ASB2 mechanism of action, we carried out a yeast two-hybrid screen and identified Elongin B as specifically associated with ASB2. By interacting with the Elongin BC complex through the BC motif, ASB2 can assemble with the Cul5-Rbx1 module to reconstitute an active E3 ubiquitin ligase complex.

MATERIALS AND METHODS

Cell Lines, Culture, and Differentiation—The COS-7 and HEK293 cell lines were grown in Petri dishes in Dulbecco’s modified Eagle’s medium supplemented with 5% fetal bovine serum and 1% penicillin-streptomycin (Invitrogen). To inhibit de novo protein synthesis, 100 μg/ml cycloheximide (Sigma) was added to HEK293 cells 48 hours post-transfection, which were harvested 5, 10, and 24 h. NB4 cells were cultured in RPMI 1640 medium (Invitrogen) with 10% fetal bovine serum (PAA Laboratories), 2 mM glutamine, and 1% penicillin-streptomycin. Exponentially growing NB4 cells were seeded at 2 × 10⁶ cells/ml 16 h before all-trans RA treatment (Sigma). Cell viability was estimated using standard trypan blue dye exclusion assay. Differentiation was assessed by (i) the percentage of cells with nitro blue tetrazolium (Sigma) deposits and (ii) cell morphology under light microscopy on May-Grünwald-Giemsa-stained cytospin slides. Sp21 cells were cultured at 27 °C in SF-900 II medium (Invitrogen) with 10% fetal bovine serum and 1% penicillin-streptomycin.

Plasmid Constructs—The ASB2 coding sequence was subcloned into (i) the pGBKTT7 vector (Clontech), (ii) the pG5ST, a derivative of pGEX-3X (Amersham Biosciences), in-frame with the glutathione S-transferase (GST) sequence, (iii) pGB5- (Stratagene)- and pBacPAK5 (Clontech)-derived vectors to direct the expression of ASB2 fused to the FLAG epitope at its N terminus (pSG5FN-ASB2 and pBacPAK5FN-ASB2, respectively), and (iv) the pAT4 vector (39) to direct the expression of ASB2 tagged with the F domain of the human estrogen receptor at its N terminus. Deletion of the SOCS box (amino acids 545–587) was generated by PCR amplification. Construction of the ASB2LPCF-mutated vectors was achieved using the QuikChange site-directed mutagenesis kit (Stratagene) and the mutated oligonucleotide sequence, as indicated in boldface, 5′-CTCAGAGACCTCCGCTACCTTTTGACGACTGCGGGTT-3′. The human Elongin B was subcloned into the pAT4 vector. The human Elongin C open reading frame was obtained by PCR amplification using bone marrow cDNA and subcloned into pSG6-derived vectors to direct the expression of Elongin C tagged with the hemagglutinin (HA) or the FLAG epitope at its N terminus. Human Ubc5 containing an N-terminal FLAG tag and a C-terminal His6, Saccharomyces cerevisiae Uba1 containing an N-terminal Myc tag and a C-terminal His6, and mammalian GST-ubiquitin expression vectors were as described (38). All constructs were verified by sequencing.

Yeast Two-hybrid Screen—A human bone marrow library was screened using the Matchmaker Two-Hybrid System-3 protocol (Clontech). Briefly, a Gal4-DNA binding domain fusion of ASB2 (pGBKTT7-ASB2) was employed as bait in the screen carried out by mating AH109-MATα-pre-transformed with pGBKT7-ASB2 to Y187-MATA library-pre-transformed cells. The AH109 transformation was carried out by standard lithium acetate protocol, and the library was maintained in Y187 strain according to manufacturer’s recommendations. Recombinant pGBKTT7-ASB2 clones were tested for protein expression by Western blotting (positive), autonomous lacZ reporter activation by the bait alone (negative), cell proliferation effects through the bait (negative), mating efficiency with Y187-MATA and were constantly maintained under selection of the auxotrophy marker Trp+. Once AH109-MATα-pGBKTT7-ASB2 was confirmed through the above protocol, mating of a sufficient large pool of these cells to the pre-transformed Y187-MATA library-carrying strain (titer, 5 × 10⁶ colony-forming units/ml) was conducted according to the manufacturer’s recommendations. Mating efficiency was determined in this case at 79%, with a total of 1947 independent colonies covering 16 10⁶ independent inserts approximately 53 times. Mated cells were spread onto selective media (SD, Clontech) for Trp (bait), Leu (prey), His (reporter 1), Ala (reporter 2), and lacZ (reporter 3) (SD-HALTX). After plating, positive clones were collected from days 8–20 after plating and re-streaked on SD-HALTX, SD-LTX, and SD-LX plates for verification of growth phenotype. Clones confirmed through this secondary screening were amplified in SD-L media, selecting only for the “prey” library insert. Plasmid DNA was finally isolated for sequencing according to standard procedures.

Expression and Purification of Recombinant Proteins in Escherichia coli—Overnight starter cultures (20 ml) of E. coli XL1-Blue (Stratagene) transformed with pGST, pGST-ASB2, pGST-Elongin B, pGST-Elongin C, and pGEX7T-2-ubiquitin were inoculated into 500 ml of LB medium and grown at 30 °C to an OD₆00 of 0.6 at 600 nm. After isopropyl-1-thio-β-D-galactopyranoside induction (0.5 mM, 2 h at 30 °C), bacteria were collected and sonicated in lysis buffer containing 50 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 10 μM ZnCl₂, 10% glycerol, 100 μg/ml lysozyme freshly supplemented with 0.1 mM dithiothreitol (DTT) and the protease inhibitor mixture for use with mammalian cell extracts (0.1%, Sigma). Uba1 and Ubc5 were expressed in E. coli BL21 (DE3). After isopropyl-1-thio-β-D-galactopyranoside induction (0.5 mM, 2 h at 30 °C), bacteria were collected and sonicated in lysis buffer containing 20 mM Tris-HCl, pH 7.9, 150 mM NaCl, 20% glycerol, 0.1% Nonidet P-40, 100 μg/ml lysozyme, 5 mM β-mercaptoethanol, 0.5 mM phenylmethylsulfonyl fluoride, and 0.1% protease inhibitor mixture for use with mammalian cell extracts. Cellular extracts were clarified by centrifugation (10,000 g/ml) and re-suspended in 0.1 M sodium acetate (pH 4.0).

To immobilize GST, GST-ASB2, GST-Elongin B, and GST-Elongin C proteins, 32 mg of extracts were incubated with 300 μl of glutathione-Sepharose beads (Amersham Biosciences) for 2.5 h at 4 °C. Beads were washed 3 times with lysis buffer and resuspended in 300 μl of the same buffer. Uba1 and Ubc5 were purified by Ni²⁺-agarose chromatography as recommended by the manufacturer (Qiagen). Uba1 and Ubc5 were eluted with 100 mM imidazole. GST-ubiquitin was purified by glutathione-Sepharose chromatography as recommended by the manufacturer (Amersham Biosciences). Purified Uba1, Ubc5, and GST-ubiquitin proteins were dialyzed against 40 mM Hepes-NaOH, pH 7.9, 60 mM potassium acetate, 1 mM MgCl₂, 0.5 mM EDTA, 10% glycerol, 2 mM DTT.

In Vitro Binding Assays—One μg of T7 promoter-fused cDNA was incubated according to the manufacturer’s recommendations (Promega) in the presence of [³⁵S]methionine for 2 h at 30 °C. In vitro binding assays were performed using 1 μg of GST fusion proteins and 5 μl of translation products of a coupled in vitro transcription/translation of cDNAs for 30 min at room temperature. After several washes to remove unbound material in washing buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM MgCl₂, 0.3 mM DTT, 5% glycerol, 0.1% Nonidet P-40), the immobilized buffer was removed by acrylamide gel electrophoresis, and analyzed by Coomassie staining and autoradiography of dried gels. Alternatively, ASB2 and the Elongin BC complex were produced using a coupled in vitro transcription/translation reaction, and immunoprecipitation experiments were carried out with anti-ASB2 antibodies as described below.

In Vivo Expression and Protein Extracts—COS-7 and HEK293 cells were transfected using calcium phosphate co-precipitation of the appropriate proteins.
ASB2 Is Involved in an Active E3 Ubiquitin Ligase Complex

RESULTS

ASB2 Bound to the Elongin BC Complex through Its BC Box—To identify binding partners for ASB2, a yeast two-hybrid screen was used with full-length ASB2 as bait together with a cDNA library from human bone marrow cells. One cDNA identified in this screen was found to encode Elongin B. The yeast strain AH109 was then transformed with Elongin B or the pACT2 empty plasmid together with the ASB2 bait plasmid and grown onto a selective media. As shown in Fig. 1A, Elongin B was found to associate specifically with ASB2 in yeast. Because Elongin B has not been shown to bind directly to BC box-containing proteins, interaction of ASB2 with Elongin B in yeast is likely to involve yeast Elongin C. To confirm the binding results from the yeast two-hybrid screen, we examined in vitro binding of Elongins B and C to ASB2. Affinity-purified GST, GST-ASB2, GST-Elongin C, and GST-Elongin B proteins expressed in E. coli were incubated with in vitro translated Elongin B and C proteins. As shown in Fig. 1B, GST-ASB2 did not bind Elongin B, whereas it bound Elongin C. Association between ASB2 and the Elongin BC complex was further assessed in coimmunoprecipitation experiments using a transcription/translation system. Both Elongins B and C coprecipitated with the wild-type ASB2 (Fig. 1C). In contrast, the ASB2ASOSCS mutant lacking the entire SOCS box did not associate with the Elongin BC complex (Fig. 1D). To confirm that ASB2 was capable of interacting with Elongin BC complex in vivo and to determine whether ASB2 associated with the Elongin BC complex through the BC motif located between amino acids 547 and 557, COS-7 cells were transfected with constructs expressing epitope-tagged elongins or ASB2. As shown in Fig. 2B, the expressed wild-type ASB2 could be co-immunoprecipitated specifically with tagged Elongins B and C. The N-terminal region of the SOCS box of ASB2, which is highly conserved in human, mouse, and chicken, includes a consensus Elongin BC binding site or BC box (Fig. 2A). The association between ASB2 and the Elongin BC complex was strongly dependent on the presence of an intact BC box since mutation of conserved residues within this motif abolished the binding of the Elongin BC complex to ASB2 (Fig. 2B). Elongin BC Binding Prevented Degradation of ASB2—We obtained high levels of wild-type ASB2 expression when Elongins B and C were co-expressed. Therefore, we assessed the effect of the Elongin BC complex binding on ASB2 stability. Cells expressing wild-type or BC-box mutant ASB2 proteins were treated with cycloheximide to block further protein synthesis for various times (Fig. 3). In the absence of cotransfected

FIG. 1. ASB2 associated with the Elongin BC complex. A, ASB2 associated with Elongin B in yeast. Clone A044 encoding Elongin B and the pACT2 empty vector (Control) were transformed into yeast strain AH109 together with the pGBK7-ASB2 vector and grown on SD/−Ade−/−His−/−Leu−/−Trp medium. B, ASB2 interacted with Elongin C. GST protein alone, GST-Elongin B, GST-Elongin C, or GST-ASB2 fusion proteins were first immobilized on glutathione-agarose beads. In vitro produced and [35S]methionine-labeled Elongin B and Elongin C were incubated with the immobilized GST proteins. The interacting complexes were resolved by SDS-PAGE and examined by autoradiography (upper panel) and Coomassie staining (lower panel). C, the cDNAs encoding wild-type ASB2, deletion mutant ASB2ASOSCS, and Elongins B and C were expressed in a coupled transcription/translation system in the presence of [35S]methionine. 15-μl aliquots of the translation products were immunoprecipitated with anti-GST antibodies. Immunoprecipitated proteins (IP anti-ASB2, right panel) as well as a 3-μl aliquot of the transcription/translation reaction (input, left panel) were fractionated by SDS-PAGE and detected by autoradiography.
Elongins B and C, both the wild-type and mutated ASB2 proteins were unstable (Fig. 3, A and B; lanes 1–4). Coexpression of Elongins B and C stabilized wild-type ASB2 protein in the presence of cycloheximide (Fig. 3, A and B; lanes 6–9). In contrast to the wild-type ASB2, elongin-mediated stabilization of ASB2 did not occur when the ASB2 elongin binding mutant was used (Fig. 3B, lanes 6–9). These results indicated that the ASB2 protein was directly stabilized by complexing with both Elongins B and C.

The ASB2-Elongin BC Complex Interacted with a Cul5-Rbx1 Module to Reconstitute an Active E3 Ubiquitin Ligase Complex—To determine whether the Elongin BC complex could function as an adaptor linking ASB2 to a Cullin-Rbx1 module and reconstituting an E3 ubiquitin ligase complex, anti-FLAG immunoprecipitations were carried out on lysates of SF21 cells co-infected with baculoviruses encoding FLAG-ASB2, Elongin B, herpes simplex virus-Elongin C, HM-Rbx1, and HA-Cul2 or -5 (Fig. 4). The ASB2-Elongin BC complex did not associate with the Cul2-Rbx1 module. However, the ASB2-Elongin BC complex did assemble with the Cul5-Rbx1 module, reconstituting a multiprotein complex containing ASB2, Elongins B and C, Rbx1, and Cul5 (Fig. 4A). The ASB2 BC-box mutant, which did not bind the Elongin BC complex, also did not assemble with the Cul5-Rbx1 module (Fig. 4B). To investigate whether the ASB2-Elongin BC-Cul5-Rbx1 complex possesses ubiquitin ligase activity, the complex was immunoaffinity-purified and assayed for its ability to activate formation of polyubiquitin chains by the E2 ubiquitin-conjugating enzyme Ubc5 in the presence of ATP, the E1 ubiquitin-activating enzyme Uba1, and GST-ubiquitin. As shown in Fig. 4C, the ASB2-Elongin BC-Cul5-Rbx1 complex stimulated formation of a ladder of GST-ubiquitin conjugates by E2 ubiquitin-conjugating enzyme, whereas the ASB2 BC-box mutant did not. As expected, formation of polyubiquitin conjugates depended on the presence of E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and ATP (Fig. 4C). The fact that the ASB2-Elongin BC complex associated with the Cul5-Rbx1 module and not with the Cul2-Rbx1 module suggested a direct contact between ASB2 and Cul5. To address this possibility, either the Cul5-Rbx1 or the Cul2-Rbx1 module was expressed in SF21 insect cells alone or together with ASB2. As shown in Fig. 5A, the Cul5-Rbx1 module associated with ASB2, whereas the Cul2-Rbx1 module did not. Although ASB2 associated with the Cul5-Rbx1 module, the resulting ASB2-Cul5-Rbx1 complex, in contrast to its ASB2-Elongin BC-Cul5-Rbx1 counterpart, only weakly supported polyubiquitination by the E2 ubiquitin-conjugating enzyme Ubc5 (Fig. 5B). The presence of an ASB2-Cul5-Rbx1 complex is unlikely to be due to an association of the insect Elongin BC complex with mammalian ASB2 and the Cul5-Rbx1 module given (i) the similar levels of immuno-
HEK293 cells were transfected in 10-cm dishes with 0.2 μg of the F-ASB2 (A) or the F-ASB2LPCF (B) expression vector either alone (left panels, −Elongin BC) or in cotransfection with 0.2 μg of F-Elongin B and 2 μg of HA-Elongin C expression vectors (right panels, +Elongin BC) as indicated. Forty-eight hours after transfection cells were treated with 100 μg/ml cycloheximide (CHX) for various times (5, 10, and 24 h). 40-μg aliquots of each whole cell extracts was immunoblotted with the indicated antibodies (Western blot). WT, wild type.

precipitated Cul5-Rbx1 observed in the absence of overexpressed Elongins B and C and (ii) the substantial decrease in polyubiquitination activity in the absence of Elongins B and C. Altogether, our results indicated that ASB2 could assemble with the Elongin BC complex and the Cul5-Rbx1 module to reconstitute an active E3 ubiquitin ligase complex.

The Endogenous ASB2 Protein Copurified with Ubiquitin Ligase Activity—We next explored whether endogenous ASB2 was involved in an E3 ubiquitin ligase complex. To this end, anti-ASB2 immunoprecipitations were carried out on untreated and RA-treated NB4 cells and assayed for their abilities to activate formation of polyubiquitin conjugates by the E2 ubiquitin-conjugating enzyme Ubc5 in the presence of the E1 ubiquitin-activating enzyme, GST-Ubiquitin, and ATP. As shown in Fig. 6, ASB2 copurified with ubiquitin ligase activity.

FIG. 3. Elongin BC complex binding stabilized ASB2 protein. HEK293 cells were transfected in 10-cm dishes with 0.2 μg of the F-ASB2 (A) or the F-ASB2LPCF (B) expression vector either alone (left panels, −Elongin BC) or in cotransfection with 0.2 μg of F-Elongin B and 2 μg of HA-Elongin C expression vectors (right panels, +Elongin BC) as indicated. Forty-eight hours after transfection cells were treated with 100 μg/ml cycloheximide (CHX) for various times (5, 10, and 24 h). 40-μg aliquots of each whole cell extracts was immunoblotted with the indicated antibodies (Western blot). WT, wild type.

FIG. 4. The ASB2-Elongin BC complex assembled with the Cul5-Rbx1 module to reconstitute a multiprotein complex with E3 ubiquitin ligase activity. A, the ASB2-Elongin BC complex interacted with the Cul5-Rbx1 module. SF21 cells were infected with baculoviruses encoding the proteins indicated. The lysates were immuno-precipitated (IP) using anti-FLAG antibodies. Crude extracts (left panel) and immune complexes (right panel) were separated by SDS-PAGE and immunoblotted with the indicated antibodies. B, the ASB2 BC box mutant that did not bind to the Elongin BC complex did not associate with the Cul5-Rbx1 module. C, the ASB2-Elongin BC-Cul5-Rbx1 complex had ubiquitin ligase activity. The cell lysates of A and B were subjected to anti-FLAG immunoaffinity purification. The purified ASB2 complex was incubated with various combinations of Ubal, Ubc5a, GSTD-Ubiquitin (GSTD-Ub) in the absence or presence of ATP to assess its ability to stimulate ubiquitination by Ubc5 by Western blot using anti-GST antibodies.
ASB2 Is Involved in an Active E3 Ubiquitin Ligase Complex

Fig. 5. The ASB2 protein associated with the Cul5-Rbx1 module. A, the Cul5-Rbx1 module did interact with the ASB2 protein, whereas the Cul2-Rbx1 module did not. S21 cells were infected with baculoviruses encoding the indicated proteins. The lysates were immunoprecipitated (IP) using anti-ASB2 antibodies. Crude extracts (left panel) and immune complexes (right panel) were separated by SDS-PAGE and immunoblotted with the indicated antibodies. WT, wild type. B, ubiquitination activity is barely detected with the exogenous ASB2-Cul5-Rbx1 complex. The cell lysates were subjected to anti-ASB2 immunopurification (left panel). The purified ASB2 complex was incubated with Uba1, Ubc5a, GST-ubiquitin (GST-Ub) in the presence of ATP (right panel). The ability of this complex to stimulate ubiquitination by Ubc5 was assessed by Western blot using anti-GST antibodies.

Fig. 6. ASB2 copurified with ubiquitin ligase activity in RA-treated NB4 cells. Cells were treated for different times with 10⁻⁶ M ATRA as indicated. 1-mg aliquots of each protein extract were immunoprecipitated with anti-ASB2 or control antibodies (control Ab). Immunoprecipitated proteins were fractionated by SDS-PAGE and analyzed for ASB2 by immunoblotting (upper panel) or assessed for their abilities to activate polyubiquitination by Ubc5 in the presence of Uba1 and ATP by immunoblotting with anti-GST antibodies (lower panel).

more, expression of Cul5 protein inhibits cell growth and retards cytokinesis by a mechanism that involves p53 (45). Although the mechanism by which Cul5 functions in these processes remains unclear, Cul5-containing ECS ubiquitin ligases have been shown to regulate the turnover of molecules involved in cell-cycle control. For example, a Cul5-containing ECS complex was shown to be involved in adenovirus-dependent ubiquitin-mediated degradation of p53 (44, 45) and in E2F1 ubiquitination (46). It is noteworthy that the ASB2 protein can inhibit cell growth and promote commitment in myeloid leukemia cells (19). The recombinant ASB2 protein can assemble into an active ECS-type E3 ubiquitin ligase complex. This together with the fact that endogenous ASB2 protein copurified with ubiquitin ligase activity in RA-treated NB4 cells suggests that, during induced differentiation of leukemic cells, the ASB2 protein may target specific proteins involved in blocking differentiation for ubiquitination and destruction by the proteasome machinery.

In this context, identification of key regulators of normal and leukemic hematopoiesis targeted for proteasomal degradation is of utmost importance. Indeed, the stability of the HOXA9 homeodomain protein was shown to be under the control of the Cul-4A ubiquitination machinery. The fact that Cul-4A is an essential component of the SCF (Skp1-Cullin-F box)-type E3 ubiquitin ligase complex, which is analogous to the ECS-type ubiquitin ligase complex, emphasizes the proteolytic targeting of HOXA9 as a novel pathway to control normal and leukemia hematopoiesis (47). Furthermore, HOXA9 overexpression is leukemogenic in mice, arresting marrow progenitors at a promyelocytic stage of differentiation (48, 49). Another example is emphasized by the role of the ubiquitin proteolytic system in the regulation of the cell cycle through the degradation of the cyclin-dependent kinase inhibitor p27Kip1 (50), which inhibits cycling of committed hematopoietic progenitors (51). Interaction of phosphorylated p27Kip1 with Skp2, a member of the F-box family of proteins that associates into a SCF-type E3 ubiquitin ligase complex, leads to specific polyubiquitination and degradation of p27Kip1 (52–54). Finally, it is remarkable that, through a functional recruitment of Elongin BC and the Cul2-Rbx1 complex to its SOCS box, SOCS1 accelerated proteasome-dependent degradation of the TEL-JAK2 fusion protein, which is the consequence of the (t;9;12) translocation associated with human leukemia, resulting in abrogation of growth of TEL-JAK2-transformed cells (55, 56). Altogether, these and our results reinforce the view that protein degradation might be an important step in control of normal and leukemia hematopoiesis. These findings provide a basis for searching degradation pathways specific to leukemogenesis. This may lead to the development of new means to inhibit oncogenic mechanisms involving ubiquitination and degradation of specific proteins in the proteasome. Further work will investigate potential regulators of normal and leukemia myelopoiesis targeted by ASB2 for proteasomal degradation.

REFERENCES

1. Melnick, A., and Licht, J. D. (1999) Blood 93, 3167–3215
2. Zelenst, A., Guider, F., Melnick, A., Waxman, S., and Licht, J. D. (2001) Oncogene 20, 7186–7203
3. Chambon, P. (1996) FASEB J. 10, 940–954
4. Kastner, P., and Chan, S. (2001) Oncogene 20, 7178–7185
5. Kastner, P., Lawrence, H. J., Waltzinger, C., Ghyselinck, N. B., Chambon, P., and Chan, S. (2001) Blood 97, 1314–1320
6. Tsai, S., and Collins, S. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7153–7157
7. Labbaye, C., Valiati, M., Testa, U., Giampaolo, A., Meccia, E., Sterpetti, P.,
ASB2 Is Involved in an Active E3 Ubiquitin Ligase Complex

Parolini, I., Pelosi, E., Bulgari, D., and Cayre, Y. E. (1994) Blood 83, 651–656.

8. Paul, C. C., Maher, S., Tolbert, M., Elbert, B. L., Wong, I., Ackerman, S. J., and Baumann, M. A. (1995) Blood 86, 3737–3744.

9. Tsai, S., Bartelmez, S., Sitnicka, E., and Collins, S. (1994) Genes Dev. 8, 2831–2841.

10. Du, C., Redner, R. L., Cooke, M. P., and Lavau, C. (1999) Blood 94, 793–802.

11. Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Ciocca, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamiri, I., Seiser, C., Lazar, M. A., Minucci, S., and Pelicci, P. G. (1998) Nature 391, 815–818.

12. Guidice, F., Ivens, S., Zhu, J., Soderstrom, M., Waxman, S., and Zelenz, A. (1998) Blood 91, 2634–2642.

13. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. (1998) Nature 391, 811–814.

14. Breitman, T. R., Collins, S. J., and Keene, B. R. (1981) Blood 57, 1000–1004.

15. Warrell, R. P., Jr., Frankel, S. R., Miller, W. H., Jr., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., Gabrilore, J., Gordon, M. S., and Dmitrovsky, E. (1991) N. Engl. J. Med. 324, 1385–1393.

16. Huang, M. E., Ye, Y. C., Chen, S. R., Chai, J. R., Lu, J. X., Zhoa, L., Gu, L. J., Castaigne, S., C., G., Wu, C., and Wang, Z. Y. (1988) Blood 72, 567–572.

17. Castaigne, S., Chomienne, C., Daniel, M. T., Ballerini, P., Berger, R., Fenaux, P., and Degos, L. (1990) Blood 76, 1704–1709.

18. Moog-Lutz, C., Peterson, E. J., Lutz, P. G., Eliason, S., C., A., Di Gioia, Y., D., D., N., S., J., C., and Koretzky, G. A. (2001) J. Biol. Chem. 276, 22375–22381.

19. Guibal, F. C., Moog-Lutz, C., Smolek, P., Di Gioia, Y., Darzykiewicz, Z., Lutz, P. G., and Cayre, Y. E. (2002) J. Biol. Chem. 277, 218–224.

20. Castini, T., and Pelicci, P. G. (1999) Oncogene 18, 3235–3243.

21. Kitsuregawa, S., Pita-Rowe, I., Sekula, D., Lowrey, C. H., Nemeth, M. J., Golub, T. R., Freemantle, S. J., and Dmitrovsky, E. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 3806–3811.

22. Fass, E., Wagner, K., Koch, H., and Tenen, D. G. (2003) EMBO J. 22, 5806–5816.

23. Park, D. J., Chumakov, A. M., Vuong, P. T., Chih, D. Y., Gombart, A. F., Miller, K. I., Schulman, B. A., Alexander, W. S., Nicola, N. A., Martin, H. M., and Kaelin, W. G., Jr. (1995) J. Biol. Chem. 270, 1444–1446.

24. Kaelin, W. G., Jr., Conaway, R. C., and Conaway, J. W. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10353–10358.

25. Kibel, A., Iliopoulos, O., DeCaprio, J. A., and Kaelin, W. G., Jr. (1998) J. Biol. Chem. 273, 1439–1446.

26. Duan, R. D., Pau, C., Burgess, W. H., Aso, T., Chen, D. Y., Garrett, K. P., Conaway, R. C., Conaway, J. W., Linehan, W. M., and Klausner, R. D. (1995) Science 269, 1439–1443.

27. Bikle, A., Desphande, S., N., O., DeCaprio, J. A., and Kaelin, W. G., Jr. (1995) Science 269, 1444–1446.

28. Aso, T., Haque, D., Barstead, R. J., Conaway, R. C., and Conaway, J. W. (1996) EMBO J. 15, 5557–5566.

29. Stebbins, C. E., Kaelin, W. G., Jr., and Pavletich, N. P. (1999) Science 284, 455–461.

30. Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Jr., Conaway, R. C., and Conaway, J. W. (1998) Genes Dev. 12, 3872–3881.

31. Zhang, J. G., Farley, A., Nicholsen, S. E., Wilson, T. A., Zugarram, L. M., Simpson, R. J., Moritz, R. L., Carly, D., Richardson, R., Hausmann, G., Kile, B. J., Kent, S. B., Alexander, W. S., Metzalf, D., Bolton, D. J., Nicola, N. A., and Baca, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2071–2076.

32. Kamura, T., Burian, D., Yan, Q., Schmidt, S. L., Lin, W. S., Quareri, E., Branton, P. E., Shilatifard, A., Conaway, R. C., and Conaway, J. W. (2001) J. Biol. Chem. 276, 29748–29753.

33. Brower, C. S., Sato, S., Tomomori-Sato, C., Kamura, T., Pasek, A., Steinar, M., Kaufr, R., Kaufr, R., Milik, S., Kaufr, R., Conaway, J. W., and Conaway, R. C. (2002) Proc. Natl. Acad. Sci. U. S. A. 97, 26587–26593.

34. Zhang, J. G., Farley, A., Nicholsen, S. E., Wilson, T. A., Zugarram, L. M., Simpson, R. J., Moritz, R. L., Carly, D., Richardson, R., Hausmann, G., Kile, B. J., Kent, S. B., Alexander, W. S., Metzalf, D., Bolton, D. J., Nicola, N. A., and Baca, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2071–2076.
ASB2 Is an Elongin BC-interacting Protein That Can Assemble with Cullin 5 and Rbx1 to Reconstitute an E3 Ubiquitin Ligase Complex
Mélina L. Heuzé, Florence C. Guibal, Charles A. Banks, Joan W. Conaway, Ronald C. Conaway, Yvon E. Cayre, Arndt Benecke and Pierre G. Lutz

J. Biol. Chem. 2005, 280:5468-5474.
doi: 10.1074/jbc.M413040200 originally published online December 8, 2004

Access the most updated version of this article at doi: 10.1074/jbc.M413040200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 56 references, 37 of which can be accessed free at http://www.jbc.org/content/280/7/5468.full.html#ref-list-1